Reilly Financial Advisors LLC lowered its position in shares of Mylan NV (NASDAQ:MYL) by 40.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,130 shares of the company’s stock after selling 2,137 shares during the period. Reilly Financial Advisors LLC’s holdings in Mylan were worth $60,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently made changes to their positions in MYL. State of New Jersey Common Pension Fund D increased its stake in shares of Mylan by 194.0% during the first quarter. State of New Jersey Common Pension Fund D now owns 1,700,000 shares of the company’s stock worth $48,178,000 after purchasing an additional 1,121,745 shares during the period. Geode Capital Management LLC increased its stake in shares of Mylan by 15.0% during the fourth quarter. Geode Capital Management LLC now owns 7,875,204 shares of the company’s stock worth $215,460,000 after purchasing an additional 1,026,731 shares during the period. FIL Ltd grew its position in Mylan by 14.1% during the first quarter. FIL Ltd now owns 6,468,868 shares of the company’s stock worth $183,327,000 after buying an additional 799,051 shares in the last quarter. Sector Gamma AS acquired a new stake in Mylan during the first quarter worth approximately $22,408,000. Finally, State of Tennessee Treasury Department grew its position in Mylan by 62.1% during the first quarter. State of Tennessee Treasury Department now owns 1,987,223 shares of the company’s stock worth $56,317,000 after buying an additional 761,160 shares in the last quarter. Institutional investors own 84.03% of the company’s stock.
A number of brokerages recently issued reports on MYL. Wolfe Research began coverage on Mylan in a research report on Friday, July 19th. They set an “outperform” rating and a $27.00 price target on the stock. Raymond James set a $31.00 price target on Mylan and gave the stock a “buy” rating in a research report on Wednesday, May 8th. BMO Capital Markets set a $36.00 price target on Mylan and gave the stock a “buy” rating in a research report on Wednesday, May 8th. UBS Group reduced their price target on Mylan to $23.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 28th. Finally, Citigroup set a $26.00 price target on Mylan and gave the stock a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have assigned a buy rating to the company. Mylan presently has a consensus rating of “Buy” and a consensus target price of $31.21.
Shares of MYL stock traded down $0.48 during trading hours on Friday, reaching $19.84. The company’s stock had a trading volume of 6,484,934 shares, compared to its average volume of 9,028,671. The company’s 50 day moving average is $18.81. The firm has a market capitalization of $10.78 billion, a P/E ratio of 4.33, a price-to-earnings-growth ratio of 0.99 and a beta of 1.77. Mylan NV has a fifty-two week low of $16.63 and a fifty-two week high of $39.59. The company has a quick ratio of 0.85, a current ratio of 1.37 and a debt-to-equity ratio of 1.15.
Mylan (NASDAQ:MYL) last issued its earnings results on Monday, July 29th. The company reported $1.03 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.95 by $0.08. The firm had revenue of $2.85 billion for the quarter, compared to the consensus estimate of $2.82 billion. Mylan had a return on equity of 18.93% and a net margin of 0.30%. The company’s revenue was up 1.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.07 EPS. On average, research analysts expect that Mylan NV will post 4.27 EPS for the current year.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Featured Story: How to read a candlestick chart
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.